Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
TYG100 utilizes proprietary S-TIR(TM) technology platform enabling specific B cell and T cell responses against tumor antigens
Foster City, CA & Hangzhou, CH, Feb 12, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa.
TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR(TM) technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by TYG oncology
CNOOC Limited Announces its 2021 Business Strategy and Development Plan
News provided by
Share this article
Share this article
HONG KONG, Feb. 4, 2021 /PRNewswire/ CNOOC Limited (the Company , SEHK: 00883,NYSE: CEO, TSX: CNU) today announced its business strategy and development plan for the year 2021.
In the extremely challenging year of 2020, under the leadership of the Board of Directors, the Company s management, together with all staff, overcame the huge impact from low oil price and the pandemic of COVID-19. During the period, while strictly implementing pandemic prevention and control measures, the Company invested great efforts in growing its oil and gas reserves and production, further reduced costs and enhanced efficiency, promoted reform and innovation, and ensured the safety in production. Thanks to all these measures, the Company s net production hit a record high of approximately 528 million barrels of oil equivalent (BOE) in 2020.
2 months ago
HONG KONG–(BUSINESS WIRE)–
Guotai Junan International”, the “
GTJAI”, Stock code:
1788.HK) announced that the Group will join hands with Nan Fung Group and Prospect Avenue Capital (PAC) to collaboratively boost development of China esports industry, supporting
Versus Programming Network (“VSPN”) to expand its scale and influence in esports eco-system, consolidating its market leader position as well as creating standardized and professional competitive sports events.
The esports industry is one of the sectors that has been greatly encouraged and supported by the government’s policies in recent years. GTJAI actively responds to and participates in the government’s policies of upgrading the esports industry structure and promoting the cultural and entertainment industry as well as the economic development through esports events. Besides, the participation in this project enables GTJAI to
Press release content from Business Wire. The AP news staff was not involved in its creation.
GTJAI to Boost VSPN’s Innovation and Development
January 22, 2021 GMT
Guotai Junan International Holdings Limited (“
Guotai Junan International ”, the “
GTJAI ”, Stock code:
1788.HK ) announced that the Group will join hands with Nan Fung Group and Prospect Avenue Capital (PAC) to collaboratively boost development of China esports industry, supporting
Versus Programming Network (“VSPN”) to expand its scale and influence in esports eco-system, consolidating its market leader position as well as creating standardized and professional competitive sports events.
ADVERTISEMENT
The esports industry is one of the sectors that has been greatly encouraged and supported by the government’s policies in recent years. GTJAI actively responds to and participates in the government’s policies of upgrading the esports industry structure and promoting the cultural and entertainm
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML). This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. AML is an aggressive disease and relapsed/refracto